• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Korro Bio Inc.

    3/18/25 7:15:45 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email
    S-8 1 krro-20250318.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 18, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    KORRO BIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    47-2324450

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    60 First Street, 2nd floor, Suite 250

    Cambridge, Massachusetts 02141

    (Address of Principal Executive Offices, Zip Code)

    Korro Bio, Inc. 2023 Stock Option and Incentive Plan

    Korro Bio, Inc. 2023 Employee Stock Purchase Plan

    (Full title of the plan)

    Ram Aiyar

    President and Chief Executive Officer

    Korro Bio, Inc.

    60 First Street, 2nd floor, Suite 250

    Cambridge, Massachusetts 02141

    (Name and address of agent for service)

    (617) 468-1999

    (Telephone number, including area code, of agent for service)

    Copies to:

    Jeffrey Cerio, Esq.

    General Counsel

    Korro Bio, Inc.

    60 First Street, 2nd floor, Suite 250

    Cambridge, Massachusetts 02141

    (617) 468-1999

     

     

    Kingsley L. Taft, Esq.

    Marianne C. Sarrazin, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    (617) 570-1000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


    EXPLANATORY NOTE

    Korro Bio, Inc. is filing this Registration Statement on Form S-8 for the purpose of registering an additional 468,863 shares of its common stock, par value $0.001 per share (the “Common Stock”), under the Korro Bio, Inc. 2023 Stock Option and Incentive Plan (the “2023 Plan”) and an additional 93,773 shares of Common Stock under the Korro Bio, Inc. 2023 Employee Stock Purchase Plan ( the “2023 ESPP”), pursuant to the provisions of each plan that provide for annual automatic increases in the number of shares of Common Stock reserved for issuance under each plan. In each case, the additional shares are of the same class as other securities for which a registration statement relating to the 2023 Plan and the 2023 ESPP has previously been filed and is effective. Accordingly, this registration statement incorporates by reference the contents of the registration statement on Form S-8 (File No. 333-275354), filed with the Securities and Exchange Commission (the “Commission”) on November 6, 2023, and the registration statement on Form S-8 (File No. 333-278245), filed with the Commission on March 26, 2024, relating to the 2023 Plan and the 2023 ESPP pursuant to General Instruction E, except with respect to Item 8. Exhibits thereof.

     


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.

    Exhibits.

    EXHIBIT INDEX

     

     

     

     

    Exhibit
    No.

    Description

     

     

     4.1

    Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on October 17, 2019).

     

     

     4.2

    Certificate of Amendment to the Restated Certificate of Incorporation, dated November 3, 2023 (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on November 6, 2023).

     

     

     4.3

    Certificate of Amendment to the Restated Certificate of Incorporation, dated November 3, 2023 (incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed on November 6, 2023).

     

     

     

     

     4.4

     

    Certificate of Amendment to the Restated Certificate of Incorporation, dated June 11, 2024 (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on June 12, 2024).

     

     

     

     4.5

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on September 23, 2020).

     

     

     5.1*

    Opinion of Goodwin Procter LLP.

     

     

     23.1*

    Consent of Ernst & Young LLP.

     

     

     23.2*

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

     

     

     24.1*

    Power of Attorney (included on signature page).

     

     

     99.1

    Korro Bio, Inc. 2023 Stock Option and Incentive Plan, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the registrant's Registration Statement on Form S-1/A filed on December 20, 2023).

     

     

     99.2

    Korro Bio, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 to the registrant's Registration Statement on Form S-1/A filed on December 20, 2023).

     

     

      107*

    Filing Fee table.

     

    *

    Filed herewith.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 18th day of March, 2025.

     

     

     

    KORRO BIO, INC.

     

     

    By:

    /s/ Ram Aiyar

     

    Name: Ram Aiyar

    Title: President, Chief Executive Officer and Director

     


    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints each of Ram Aiyar and Vineet Agarwal, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

    NAME

    TITLE

    DATE

    /s/ Ram Aiyar

    Ram Aiyar

    President, Chief Executive Officer and Director
    Principal Executive Officer, Interim Principal Financial Officer

    March 18, 2025

    /s/ Oliver Dolan

    Oliver Dolan

    Senior Vice President, Finance

    Interim Principal Accounting Officer

     

    March 18, 2025

    /s/ Ali Behbahani

    Ali Behbahani

    Director

     

     

    March 18, 2025

    /s/ Nessan Birmingham

    Nessan Birmingham

    Director

    March 18, 2025

     

     

     

    /s/ Jean-Francois Formela

    Jean-Francois Formela

    Director

    March 18, 2025

     

     

     

    /s/ Katharine Knobil

    Katharine Knobil

    Director

    March 18, 2025

     

     

     

    /s/ Rachel Meyers

    Rachel Meyers

    Director

    March 18, 2025

     

     

     

    /s/ Timothy Pearson

    Timothy Pearson

    Director

    March 18, 2025

     

     


    Get the next $KRRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    4/29/2025$74.00Overweight
    Cantor Fitzgerald
    4/16/2025$25.00Buy
    Chardan Capital Markets
    1/10/2025$155.00Outperform
    Oppenheimer
    10/21/2024$153.00Strong Buy
    Raymond James
    8/14/2024$180.00Outperform
    William Blair
    3/28/2024$100.00 → $115.00Buy
    H.C. Wainwright
    2/27/2024$120.00Outperform
    BMO Capital Markets
    12/4/2023$100.00Buy
    H.C. Wainwright
    More analyst ratings

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Korro to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference Dr. Aiyar and Dr. Olugemo, will present on Monday, June 9, 2025, at 4:00 p.m. ET. A live webc

      5/14/25 4:05:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

      —Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025  —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027   —Second development candidate expected to be announced in 2025  —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketable securities     CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of gene

      5/7/25 4:30:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

      4/1/25 7:30:00 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Behbahani Ali

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      6/12/25 4:40:18 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Meyers Rachel

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      6/12/25 4:32:03 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bermingham Nessan

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      6/12/25 4:29:03 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 7:54:42 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 3:04:22 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 12:21:08 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Korro Bio with a new price target

      Cantor Fitzgerald initiated coverage of Korro Bio with a rating of Overweight and set a new price target of $74.00

      4/29/25 8:10:45 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Korro Bio with a new price target

      Chardan Capital Markets initiated coverage of Korro Bio with a rating of Buy and set a new price target of $25.00

      4/16/25 9:07:30 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Korro Bio with a new price target

      Oppenheimer initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $155.00

      1/10/25 8:59:40 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    SEC Filings

    See more
    • Korro Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Korro Bio, Inc. (0001703647) (Filer)

      6/11/25 4:23:09 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Korro Bio Inc.

      10-Q - Korro Bio, Inc. (0001703647) (Filer)

      5/7/25 4:40:22 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - Korro Bio, Inc. (0001703647) (Filer)

      5/7/25 4:35:10 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mathers Edward T bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:19 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Florence Anthony A. Jr. bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:26 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yang Rick bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:16 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

      4/1/25 7:30:00 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

      - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

      11/12/24 4:05:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care